LONDON – Circassia Pharmaceuticals plc is raising £275 million (US$432 million) in a placing and open offer to fund the acquisition of two fellow respiratory specialists – Aerocrine AB, with a sales force and two commercial products, and Prosonix Ltd., which has an advanced portfolio of generic inhaled asthma drugs, the first of which is due to be approved imminently.